{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:41:21Z","timestamp":1765273281961,"version":"3.46.0"},"reference-count":41,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0021_s_001_w2aab3b7b2b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d19953255e2939_w2aab3b7b2b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases from ovarian cancer have been shown to have a role in recurrent ovarian cancer, but are still not considered standard therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0021_s_002_w2aab3b7b2b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d19953255e2948_w2aab3b7b2b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>From March 2005 to July 2013, 41 patients who underwent 44 CRS and HIPEC for peritoneal metastases in recurrent ovarian cancer were included in this study. Details were obtained from a prospectively maintained database. Our aim was to report our 5-year overall and disease-free survivals, as well as prognostic factors for survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0021_s_003_w2aab3b7b2b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d19953255e2957_w2aab3b7b2b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                    <jats:p>Median age was 50 years old (range 23\u201373). Median duration of surgery was 510\u2006min (range 230\u2013840) and median peritoneal carcinomatosis index (PCI) score was 9.5 (range 0\u201331). About 92.7% of the patients had completeness of cytoreduction (CC) scores of 0 or 1. Median follow-up was 43.9 months (range 0.7\u2013108.9). There were no mortalities and the high-grade morbidity rate was 31.8%. Median overall survival was 42.8 months (range 28.6\u201399.9) 5-year overall and disease-free survivals were 49.3% and 7.5% respectively. On multivariate analysis, histology and CC score were significantly associated with overall survival while histology and disease-free interval were associated with disease-free survival. The odds of developing a high-grade complication more than doubled for each additional surgical procedure performed (p=0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0021_s_004_w2aab3b7b2b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d19953255e2966_w2aab3b7b2b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>CRS and HIPEC can attain prolonged survival in selected patients with peritoneal metastasis in recurrent ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0021","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T17:15:55Z","timestamp":1510247755000},"page":"171-179","source":"Crossref","is-referenced-by-count":2,"title":["Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer with peritoneal metastasis: a prospective registry study on 41 patients"],"prefix":"10.1515","volume":"2","author":[{"given":"Melissa Ching Ching","family":"Teo","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , 11 Hospital Drive , Singapore 169610 , Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claramae Shulyn","family":"Chia","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , 11 Hospital Drive , Singapore 169610 , Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Epidemiological Sciences , National Cancer Centre Singapore , 11 Hospital Drive , Singapore 169610 , Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Hwei Ching","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , 11 Hospital Drive , Singapore 169610 , Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whay Kuang","family":"Chia","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology , National Cancer Centre Singapore , 11 Hospital Drive , Singapore 169610 , Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khee Chee","family":"Soo","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , 11 Hospital Drive , Singapore 169610 , Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Bonnefoi H, A\u2019Hern RP, Fisher C, Macfarlene V, Barton D, Blake P, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17:767\u201375.10.1200\/JCO.1999.17.3.76710071265","key":"2025120909190750103_j_pp-2017-0021_ref_001_w2aab3b7b2b1b6b1ab1b6b1Aa","DOI":"10.1200\/JCO.1999.17.3.767"},{"unstructured":"Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnaqin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical app-2017-0021roach. Gynecol Oncol. 2004;94:650\u201354.10.1016\/j.ygyno.2004.01.029","key":"2025120909190750103_j_pp-2017-0021_ref_002_w2aab3b7b2b1b6b1ab1b6b2Aa"},{"unstructured":"Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upp-2017-0021er abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083\u201390.1689027710.1016\/j.ygyno.2006.06.028","key":"2025120909190750103_j_pp-2017-0021_ref_003_w2aab3b7b2b1b6b1ab1b6b3Aa"},{"unstructured":"Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278\u201387.10.1006\/gyno.1998.514510053096","key":"2025120909190750103_j_pp-2017-0021_ref_004_w2aab3b7b2b1b6b1ab1b6b4Aa"},{"unstructured":"Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26\u201331.10.1016\/j.ygyno.2009.03.01819395008","key":"2025120909190750103_j_pp-2017-0021_ref_005_w2aab3b7b2b1b6b1ab1b6b5Aa"},{"unstructured":"Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A, Egger H. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol. 2007;106:591\u201395.1761905510.1016\/j.ygyno.2007.05.023","key":"2025120909190750103_j_pp-2017-0021_ref_006_w2aab3b7b2b1b6b1ab1b6b6Aa"},{"unstructured":"Salani R, Zahurak ML, Santillan A, Giuntoli RL, 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107:495\u201399.10.1016\/j.ygyno.2007.08.00317854870","key":"2025120909190750103_j_pp-2017-0021_ref_007_w2aab3b7b2b1b6b1ab1b6b7Aa"},{"unstructured":"Leitao MM, Jr, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol. 2009;36:106\u201311.1933224510.1053\/j.seminoncol.2008.12.002","key":"2025120909190750103_j_pp-2017-0021_ref_008_w2aab3b7b2b1b6b1ab1b6b8Aa"},{"unstructured":"Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007 Oct;14(5):195\u2013208.10.3747\/co.2007.14817938703","key":"2025120909190750103_j_pp-2017-0021_ref_009_w2aab3b7b2b1b6b1ab1b6b9Aa"},{"unstructured":"Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynaecol Oncol. 2009;112:265\u201374.10.1016\/j.ygyno.2008.08.033","key":"2025120909190750103_j_pp-2017-0021_ref_010_w2aab3b7b2b1b6b1ab1b6c10Aa"},{"unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u201355.10.1056\/NEJM1996122633526038960474","key":"2025120909190750103_j_pp-2017-0021_ref_011_w2aab3b7b2b1b6b1ab1b6c11Aa"},{"unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from app-2017-0021endiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449\u201356.10.1200\/JCO.2011.39.716622614976","key":"2025120909190750103_j_pp-2017-0021_ref_012_w2aab3b7b2b1b6b1ab1b6c12Aa"},{"unstructured":"Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg. 2005;92:153\u201358.10.1002\/bjs.486215685704","key":"2025120909190750103_j_pp-2017-0021_ref_013_w2aab3b7b2b1b6b1ab1b6c13Aa"},{"doi-asserted-by":"crossref","unstructured":"Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31:49\u201354.10.1097\/COC.0b013e318068418118376228","key":"2025120909190750103_j_pp-2017-0021_ref_014_w2aab3b7b2b1b6b1ab1b6c14Aa","DOI":"10.1097\/COC.0b013e3180684181"},{"unstructured":"Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41\u201349.17039392","key":"2025120909190750103_j_pp-2017-0021_ref_015_w2aab3b7b2b1b6b1ab1b6c15Aa"},{"unstructured":"Verwaal VJ, van Ruth S, de Bree E, Van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.10.1200\/JCO.2003.04.18714551293","key":"2025120909190750103_j_pp-2017-0021_ref_016_w2aab3b7b2b1b6b1ab1b6c16Aa"},{"unstructured":"Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518\u201321.1512346110.1245\/ASO.2004.09.008","key":"2025120909190750103_j_pp-2017-0021_ref_017_w2aab3b7b2b1b6b1ab1b6c17Aa"},{"unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011\u201319.10.1200\/JCO.2006.07.114216921055","key":"2025120909190750103_j_pp-2017-0021_ref_018_w2aab3b7b2b1b6b1ab1b6c18Aa"},{"unstructured":"Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol. 1997;123:6\u201312.10.1007\/BF012126088996534","key":"2025120909190750103_j_pp-2017-0021_ref_019_w2aab3b7b2b1b6b1ab1b6c19Aa"},{"unstructured":"Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27:365\u201374. Review.1190892910.1053\/ctrv.2001.0232","key":"2025120909190750103_j_pp-2017-0021_ref_020_w2aab3b7b2b1b6b1ab1b6c20Aa"},{"unstructured":"Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynaecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: reportfrom the Fourth Ovarian Cancer Consensus Conference. Int J Gynaecol Cancer. 2011;21:750\u201355.10.1097\/IGC.0b013e31821b2568","key":"2025120909190750103_j_pp-2017-0021_ref_021_w2aab3b7b2b1b6b1ab1b6c21Aa"},{"unstructured":"Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18:3793\u2013803. Review.2259142210.2174\/138161212802002616","key":"2025120909190750103_j_pp-2017-0021_ref_022_w2aab3b7b2b1b6b1ab1b6c22Aa"},{"unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.10.1097\/00000658-199501000-000047826158","key":"2025120909190750103_j_pp-2017-0021_ref_023_w2aab3b7b2b1b6b1ab1b6c23Aa"},{"unstructured":"Sugarbaker PH, Jablonsky KA. Prognostic features of 51 colorectal and 130 app-2017-0021endiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124\u201332.10.1097\/00000658-199502000-000027857141","key":"2025120909190750103_j_pp-2017-0021_ref_024_w2aab3b7b2b1b6b1ab1b6c24Aa"},{"unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.884996210.1007\/978-1-4613-1247-5_23","key":"2025120909190750103_j_pp-2017-0021_ref_025_w2aab3b7b2b1b6b1ab1b6c25Aa"},{"unstructured":"Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26:93\u2013109.10.1016\/j.hoc.2011.10.00422244664","key":"2025120909190750103_j_pp-2017-0021_ref_026_w2aab3b7b2b1b6b1ab1b6c26Aa"},{"unstructured":"Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005;92:1026\u201332.10.1038\/sj.bjc.660246615770211","key":"2025120909190750103_j_pp-2017-0021_ref_027_w2aab3b7b2b1b6b1ab1b6c27Aa"},{"doi-asserted-by":"crossref","unstructured":"Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702\u201310.10.1245\/s10434-006-9058-017009163","key":"2025120909190750103_j_pp-2017-0021_ref_028_w2aab3b7b2b1b6b1ab1b6c28Aa","DOI":"10.1245\/s10434-006-9058-0"},{"unstructured":"G\u00fcng \u00f6r M, Orta\u00e7 F, Arvas M, K\u00f6sebay D, S\u00f6nmezer M, K\u00f6se K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97:74\u201379.1579044010.1016\/j.ygyno.2004.11.057","key":"2025120909190750103_j_pp-2017-0021_ref_029_w2aab3b7b2b1b6b1ab1b6c29Aa"},{"unstructured":"Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504\u201312.1173396310.1006\/gyno.2001.6404","key":"2025120909190750103_j_pp-2017-0021_ref_030_w2aab3b7b2b1b6b1ab1b6c30Aa"},{"doi-asserted-by":"crossref","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435\u201343.10.1016\/j.ejso.2013.09.03024209430","key":"2025120909190750103_j_pp-2017-0021_ref_031_w2aab3b7b2b1b6b1ab1b6c31Aa","DOI":"10.1016\/j.ejso.2013.09.030"},{"unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570\u201375.10.1245\/s10434-014-4157-925391263","key":"2025120909190750103_j_pp-2017-0021_ref_032_w2aab3b7b2b1b6b1ab1b6c32Aa"},{"unstructured":"Tan GH, Ong WS, Chia CS, Tham CK, Soo KC, Teo MC. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?. Int J Hyperthermia. 2016;32(3):281\u201388.10.3109\/02656736.2015.113548526862667","key":"2025120909190750103_j_pp-2017-0021_ref_033_w2aab3b7b2b1b6b1ab1b6c33Aa"},{"unstructured":"Chia CS, Tan WJ, Wong J, Tan GH, Lim C, Wang W, et al. Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2014;40(8):909\u20131621.2476844510.1016\/j.ejso.2013.12.028","key":"2025120909190750103_j_pp-2017-0021_ref_034_w2aab3b7b2b1b6b1ab1b6c34Aa"},{"unstructured":"Tan WJ, Wong J, Chia CS, Tan G, Soo KC, Teo M. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy \u2013 an Asian perspective. Ann Surg Oncol. 2013;20(13):4219\u20132.10.1245\/s10434-013-3133-024008554","key":"2025120909190750103_j_pp-2017-0021_ref_035_w2aab3b7b2b1b6b1ab1b6c35Aa"},{"unstructured":"Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2905\u201313.27016293","key":"2025120909190750103_j_pp-2017-0021_ref_036_w2aab3b7b2b1b6b1ab1b6c36Aa"},{"unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.10.1200\/JCO.2012.42.050522529265","key":"2025120909190750103_j_pp-2017-0021_ref_037_w2aab3b7b2b1b6b1ab1b6c37Aa"},{"unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302\u201308.10.1200\/JCO.2013.51.448924637997","key":"2025120909190750103_j_pp-2017-0021_ref_038_w2aab3b7b2b1b6b1ab1b6c38Aa"},{"doi-asserted-by":"crossref","unstructured":"Gelmon K A, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852\u201361.10.1016\/S1470-2045(11)70214-521862407","key":"2025120909190750103_j_pp-2017-0021_ref_039_w2aab3b7b2b1b6b1ab1b6c39Aa","DOI":"10.1016\/S1470-2045(11)70214-5"},{"unstructured":"Kaye S B, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372\u201379.2220375510.1200\/JCO.2011.36.9215","key":"2025120909190750103_j_pp-2017-0021_ref_040_w2aab3b7b2b1b6b1ab1b6c40Aa"},{"unstructured":"Fagotti A, Costantini B, Vizzielli G, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long -term analysis of clinical outcome. Gynecol Oncol. 2011;122:221\u201325.10.1016\/j.ygyno.2011.04.00821543112","key":"2025120909190750103_j_pp-2017-0021_ref_041_w2aab3b7b2b1b6b1ab1b6c41Aa"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/4\/article-p171.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0021\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:36:45Z","timestamp":1765273005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0021\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12,1]]},"published-print":{"date-parts":[[2017,12,20]]}},"alternative-id":["10.1515\/pp-2017-0021"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0021","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"type":"electronic","value":"2364-768X"},{"type":"print","value":"2364-7671"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}